The status of platinum anticancer drugs in the clinic and in clinical trials

Dalton Transactions - Tập 39 Số 35 - Trang 8113 - 2010
Nial J. Wheate1, Shonagh Walker1, Gemma E. Craig1, Rabbab Oun1
1Strathclyde Institute of Pharmacy, and Biomedical Sciences, University of Strathclyde, John Arbuthnott Building, 27 Taylor Street, Glasgow, UK

Tóm tắt

Từ khóa


Tài liệu tham khảo

Hoeschele, 2009, Dalton Trans., 10648

Kelland, 2007, Nat. Rev. Cancer, 7, 573, 10.1038/nrc2167

Puckett, 2010, Dalton Trans., 39, 1159, 10.1039/B922209J

Jamieson, 1999, Chem. Rev., 99, 2467, 10.1021/cr980421n

Chapman, 2010, J. Am. Chem. Soc., 132, 1946, 10.1021/ja908419j

Piccart, 2001, Ann. Oncol., 12, 1195, 10.1023/A:1012259625746

Kehe, 2005, Toxicology, 214, 198, 10.1016/j.tox.2005.06.014

Neidle, 1980, J. Inorg. Biochem., 13, 205, 10.1016/S0162-0134(00)80069-0

Frey, 1993, Inorg. Chem., 32, 1333, 10.1021/ic00060a005

Laurie, 2010, Cancer, 116, 362, 10.1002/cncr.24745

Penson, 2010, J. Clin. Oncol., 28, 154, 10.1200/JCO.2009.22.7900

Boulikas, 2003, Oncol. Rep., 10, 1663

Kasparkova, 2008, Chem.–Eur. J., 14, 1330, 10.1002/chem.200701352

Lordick, 2010, Br. J. Cancer, 102, 500, 10.1038/sj.bjc.6605521

Zarate, 2010, Br. J. Cancer, 102, 987, 10.1038/sj.bjc.6605595

Kuwahara, 2009, Int. J. Med. Sci., 6, 305, 10.7150/ijms.6.305

Alberto, 2009, J. Phys. Chem. B, 113, 14473, 10.1021/jp9056835

Kawai, 2005, Biol. Pharm. Bull., 28, 1385, 10.1248/bpb.28.1385

Boulikas, 2007, Cancer Ther., 5, 537

Kodaira, 2006, Anticancer Res., 26, 2265

Kurita, 2010, Cancer Chemother. Pharmacol., 65, 503, 10.1007/s00280-009-1056-z

Gong, 2009, Cancer Chemother. Pharmacol., 64, 327, 10.1007/s00280-008-0874-8

Oshita, 2004, J. Exp. Ther. Oncol., 4, 343

Yamashita, 2006, Dis. Esophagus., 19, 15, 10.1111/j.1442-2050.2006.00531.x

Zheng, 2010, Jpn. J. Clin. Oncol., 40, 425, 10.1093/jjco/hyp183

Mross, 1992, Onkologie, 15, 139

Gietema, 1993, Anti-Cancer Drugs, 4, 51, 10.1097/00001813-199302000-00007

Gietema, 1995, Br. J. Cancer, 71, 1302, 10.1038/bjc.1995.252

Kavanagh, 1995, Gynecol. Oncol., 58, 106, 10.1006/gyno.1995.1191

Degardin, 1995, Invest. New Drugs, 13, 253, 10.1007/BF00873809

Welink, 1999, Clin. Cancer Res., 5, 2349

Gietema, 1993, Br. J. Cancer, 67, 396, 10.1038/bjc.1993.73

Manegold, 1996, Onkologie, 19, 248

Ma, 2009, Linchuang Zhongliuxue Zazhi, 14, 816

Sternberg, 1997, Ann. Oncol., 8, 695, 10.1023/A:1008269432176

Limited, 2003, Drugs R&D, 4, 369, 10.2165/00126839-200304060-00008

Shi, 2008, Xiandai Zhongxiyi Jiehe Zazhi, 17, 5105

Shchepinov, 2001, Nucleic Acids Res., 29, 3864, 10.1093/nar/29.18.3864

Kim, 1994, J. Med. Chem., 37, 1471, 10.1021/jm00036a013

Kim, 1995, Cancer Chemother. Pharmacol., 37, 1, 10.1007/BF00685622

Kim, 1995, Cancer Chemother. Pharmacol., 35, 441, 10.1007/s002800050260

Lee, 2006, Anti-Cancer Drugs, 17, 377, 10.1097/01.cad.0000205033.08838.c7

Kim, 2001, Cancer, 91, 1549, 10.1002/1097-0142(20010415)91:8<1549::AID-CNCR1164>3.0.CO;2-2

Lee, 2005, Cancer Res. Treat., 37, 208, 10.4143/crt.2005.37.4.208

Oh, 2003, Cancer Res. Treat., 35, 117, 10.4143/crt.2003.35.2.117

Kim, 1999, Cancer, 86, 1109, 10.1002/(SICI)1097-0142(19991001)86:7<1109::AID-CNCR3>3.0.CO;2-G

Min, 2004, J. Korean Med. Sci., 19, 369, 10.3346/jkms.2004.19.3.369

Ahn, 2002, Cancer Chemother. Pharmacol., 50, 104, 10.1007/s00280-002-0483-x

Lee, 2009, Cancer Res. Treat., 41, 12, 10.4143/crt.2009.41.1.12

Ohstu, 2003, J. Clin. Oncol., 21, 54, 10.1200/JCO.2003.04.130

Braddock, 1975, Chem.-Biol. Interact., 11, 145, 10.1016/0009-2797(75)90095-2

Connors, 1972, Chem.-Biol. Interact., 5, 415, 10.1016/0009-2797(72)90078-6

Connors, 1975, FEBS Lett., 57, 223, 10.1016/0014-5793(75)80305-X

Owens, 1985, Cancer Chemother. Pharmacol., 14, 253, 10.1007/BF00258128

Thatcher, 1982, Cancer Chemother. Pharmacol., 9, 13, 10.1007/BF00296754

Hill, 1982, Anticancer Res., 2, 173

Boulikas, 2007, Cancer Ther., 5, 537

Gibbons, 1989, Cancer Res., 49, 1402

Anderson, 1986, Cancer Treat. Rep., 70, 997

Rose, 1982, Cancer Treat. Rep., 66, 135

Rahman, 1988, Cancer Res., 48, 1745

Parker, 1993, Cancer Res., 53, 242

Schilder, 1994, Cancer Res., 54, 709

Tutsch, 1999, Invest. New Drugs, 17, 63, 10.1023/A:1006223100561

O'Rourke, 1994, Anti-Cancer Drugs, 5, 520, 10.1097/00001813-199410000-00002

O'Brien, 1992, Cancer Res., 52, 4130

Kobayahi, 1991, Invest. New Drugs, 9, 313, 10.1007/BF00183571

Elliott, 1994, Cancer Res., 54, 4412

Perez, 1991, Int. J. Cancer, 48, 265, 10.1002/ijc.2910480219

Takahashi, 1993, Cancer Chemother. Pharmacol., 33, 31, 10.1007/BF00686019

Takahashi, 1996, Oncology, 53, 68, 10.1159/000227538

O'Dwyer, 1992, Cancer Res., 52, 6746

Theriault, 1993, Cancer Chemother. Pharmacol., 31, 333, 10.1007/BF00685681

Theriault, 1996, Cancer Chemother. Pharmacol., 38, 289, 10.1007/s002800050484

Bitha, 1989, J. Med. Chem., 32, 2015, 10.1021/jm00128a052

Meijer, 1992, Cancer Res., 52, 6885

Kelland, 1992, Plat. Met. Rev., 36, 178, 10.1595/003214092X364178184

Kudelka, 1997, Anti-Cancer Drugs, 8, 649, 10.1097/00001813-199708000-00001

Dodion, 1991, Ann. Oncol., 2, 589, 10.1093/oxfordjournals.annonc.a058026

Willemse, 1991, Proc. Am. Assoc. Clin. Oncol., 10, 191

Markman, 1993, J. Cancer Res. Clin. Oncol., 119, 234, 10.1007/BF01624436

Piccart, 1991, Proc. Am. Assoc. Cancer Res., 32, 1222

Aamdal, 1997, Cancer Chemother. Pharmacol., 40, 439, 10.1007/s002800050683

Olver, 1995, Am. J. Clin. Oncol., 18, 56, 10.1097/00000421-199502000-00012

Jones, 1991, Br. J. Cancer, 63, 7

Tanis, 1991, Eur. J. Cancer Clin. Oncol., 27, 268, 10.1016/0277-5379(91)90513-D

Sørensen, 1985, Cancer Chemother. Pharmacol., 15, 97, 10.1007/BF00257516

Colombo, 1986, Cancer Treat. Rep., 70, 793

Tanis, 1992, Oncology, 49, 99, 10.1159/000227020

Drees, 1995, Eur. J. Cancer, 31, 356, 10.1016/0959-8049(94)00513-5

Bagrova, 2001, Voprosy Onkologii, 47, 752

Akamatsu, 1992, Br. J. Cancer, 66, 827, 10.1038/bjc.1992.368

Lebwohl, 1998, Eur. J. Cancer, 34, 1522, 10.1016/S0959-8049(98)00224-X

Kobayashi, 1991, Invest. New Drugs, 9, 313, 10.1007/BF00183571

Tamura, 1990, Cancer, 66, 2059, 10.1002/1097-0142(19901115)66:10<2059::AID-CNCR2820661003>3.0.CO;2-#

Aoyama, 1992, Cancer Chemother., 19, 1033

Kato, 1992, Cancer Chemother., 19, 1285

Pendyala, 1988, Cancer Res, 48, 3533

Bramwell, 1985, Cancer Treat. Rep., 69, 409

Paolozzi, 1988, Invest. New Drugs, 6, 199, 10.1007/BF00175398

Chawla, 1988, Invest. New Drugs, 6, 311, 10.1007/BF00173650

Sessa, 1988, J. Clin. Oncol., 6, 98, 10.1200/JCO.1988.6.1.98

de Wit, 1991, Eur. J. Cancer Clin. Oncol., 27, 1383, 10.1016/0277-5379(91)90015-6

Cantwell, 1986, Cancer Chemother. Pharmacol., 18, 286, 10.1007/BF00273405

Hortobagyi, 1987, Cancer Treat. Rep., 71, 1193

Vermorken, 1993, Ann. Oncol., 4, 303, 10.1093/annonc/4.suppl_4.S41

Casper, 1988, Invest. New Drugs, 6, 87, 10.1007/BF00195365

Meisner, 1989, Am. J. Clin. Oncol., 12, 129, 10.1097/00000421-198904000-00008

Nitschke, 1992, Invest. New Drugs, 10, 93, 10.1007/BF00873123

Castleberry, 1994, J. Clin. Oncol., 12, 1616, 10.1200/JCO.1994.12.8.1616

Friedman, 1992, J. Clin. Oncol., 10, 249, 10.1200/JCO.1992.10.2.249

Drasga, 1987, Cancer Treat. Rep., 71, 863

Murphy, 1992, Invest. New Drugs, 10, 327, 10.1007/BF00944190

Goldenberg, 1990, Invest. NewDrugs, 8, 71

Petrelli, 1989, Cancer Chemother. Pharmacol., 23, 61

Asbury, 1989, Am. J. Clin. Oncol., 12, 416, 10.1097/00000421-198910000-00011

Blitzer, 1988, Am. J. Clin. Oncol., 11, 650, 10.1097/00000421-198812000-00012

McGuire, 1986, Invest. New Drugs, 4, 181, 10.1007/BF00194600

Lira-Peurto, 1991, Cancer Chemother. Pharmacol., 28, 391, 10.1007/BF00685695

Kramer, 1988, Am. J. Clin. Oncol., 11, 643, 10.1097/00000421-198812000-00010

Granfortuna, 1989, Am. J. Clin. Oncol., 12, 355, 10.1097/00000421-198908000-00016

Abele, 1987, Eur. J. Cancer Clin. Oncol., 23, 387, 10.1016/0277-5379(87)90374-9

Clavel, 1988, Eur. J. Cancer Clin. Oncol., 24, 1345, 10.1016/0277-5379(88)90226-X

Anderson, 1988, Eur. J. Cancer Clin. Oncol., 24, 1471, 10.1016/0277-5379(88)90338-0

Saito, 1995, ORL, 57, 250, 10.1159/000276752

White, 2006, Br. J. Cancer, 95, 822, 10.1038/sj.bjc.6603345

Bandak, 1999, Anti-Cancer Drugs, 10, 911, 10.1097/00001813-199911000-00007

Newman, 1999, Cancer Chemother. Pharmacol., 43, 1, 10.1007/s002800050855

Working, 1998, Toxicol. Sci., 46, 155

Vaage, 1999, Int. J. Cancer, 80, 134, 10.1002/(SICI)1097-0215(19990105)80:1<134::AID-IJC24>3.0.CO;2-Q

Harrington, 2001, Ann. Oncol., 12, 493, 10.1023/A:1011199028318

Veal, 2001, Br. J. Cancer, 84, 1029, 10.1054/bjoc.2001.1723

Terwogt, 2002, Cancer Chemother. Pharmacol., 49, 201, 10.1007/s002800100371

Liu, 2001, Proc. Am. Soc. Clin. Oncol., 20

Rosenthal, 2002, Invest. New Drugs, 20, 343, 10.1023/A:1016201732368

Vokes, 2000, Clin. Lung Cancer, 2, 128, 10.3816/CLC.2000.n.025

Kim, 2001, Lung Cancer, 34, 427, 10.1016/S0169-5002(01)00278-1

Vail, 2002, Cancer Chemother. Pharmacol., 50, 131, 10.1007/s00280-002-0469-8

Schroeder, 2007, Langmuir, 23, 4019, 10.1021/la0631668

Schroeder, 2009, J. Controlled Release, 137, 63, 10.1016/j.jconrel.2009.03.007

Lauterzstain, 1986, Cancer Chemother. Pharmacol., 18, 93, 10.1007/BF00253076

Perez-Soler, 1988, CancerRes., 48, 4509

Khokhar, 1991, J. Med. Chem., 34, 325, 10.1021/jm00105a051

Perez-Soler, 1989, Cancer Chemother. Pharmacol., 24, 1, 10.1007/BF00254097

Han, 1993, Cancer Res., 53, 4913

Han, 1996, Cancer Chemother. Pharmacol., 39, 17, 10.1007/s002800050533

Han, 1994, Anti-Cancer Drugs, 5, 64, 10.1097/00001813-199402000-00010

Perez-Soler, 1987, Cancer Res., 47, 6462

Perez-Soler, 1990, Cancer Res., 50, 4254

Dragovich, 2006, Cancer Chemother. Pharmacol., 58, 759, 10.1007/s00280-006-0235-4

Rothenberg, 2003, J. Clin. Oncol., 21, 2059, 10.1200/JCO.2003.11.126

Perez-Soler, 1997, Clinical Cancer Res., 3, 373

Lu, 2005, J. Clin. Oncol., 23, 3495, 10.1200/JCO.2005.00.802

Verschraegen, 2003, J. Cancer Res. Clin. Oncol., 129, 549, 10.1007/s00432-003-0481-3

Wheate, 2005, Curr. Med. Chem.: Anti-Cancer Agents, 5, 267

Di Blasi, 1998, Anticancer Res., 18, 3113

Roberts, 1999, J. Inorg. Biochem., 77, 47, 10.1016/S0162-0134(99)00137-3

Roberts, 1999, J. Inorg. Biochem., 77, 51, 10.1016/S0162-0134(99)00147-6

Perego, 1999, J. Inorg. Biochem., 77, 59, 10.1016/S0162-0134(99)00142-7

McGregor, 2002, JBIC, J. Biol. Inorg. Chem., 7, 397, 10.1007/s00775-001-0312-4

Kloster, 1999, Biochemistry, 38, 14731, 10.1021/bi991202e

Brabec, 1999, Biochemistry, 38, 6781, 10.1021/bi990124s

Kasparkova, 2002, J. Biol. Chem., 277, 48076, 10.1074/jbc.M208016200

Qu, 2003, JBIC, J. Biol. Inorg. Chem., 8, 19, 10.1007/s00775-002-0383-x

Qu, 2004, J. Inorg. Biochem., 98, 1585, 10.1016/j.jinorgbio.2004.07.011

Hegmans, 2004, J. Am. Chem. Soc., 126, 2166, 10.1021/ja036105u

Qu, 2009, JBIC, J. Biol. Inorg. Chem., 14, 969, 10.1007/s00775-009-0509-5

Ruhayel, 2009, Chem.–Eur. J., 15, 9365, 10.1002/chem.200900958

McGregor, 1999, J. Inorg. Biochem., 77, 43, 10.1016/S0162-0134(99)00136-1

McGregor, 2002, J. Inorg. Biochem., 91, 212, 10.1016/S0162-0134(02)00398-7

Komeda, 2006, J. Am. Chem. Soc., 128, 16092, 10.1021/ja062851y

Liu, 2006, Biochemistry, 45, 4248, 10.1021/bi052517z

Billecke, 2006, Neuro-Oncology, 8, 215, 10.1215/15228517-2006-004

Orlandi, 2001, Eur. J. Cancer, 37, 649, 10.1016/S0959-8049(00)00445-7

Riccardi, 2001, Cancer Chemother. Pharmacol., 47, 498, 10.1007/s002800000264

Colella, 2001, Br. J. Cancer, 84, 1387, 10.1054/bjoc.2001.1751

Servidei, 2001, Eur. J. Cancer, 37, 930, 10.1016/S0959-8049(01)00061-2

Manzotti, 2000, Clin. Cancer Res., 6, 2626

Perego, 1999, Mol. Pharm., 55, 528

Pratesi, 1999, Br. J. Cancer, 80, 1912, 10.1038/sj.bjc.6690620

Sessa, 2000, Ann. Oncol., 11, 977, 10.1023/A:1008302309734

Calvert, 2000, Proc. Am. Soc. Clin. Oncol, 19, abstr 921F

Jodrell, 2004, Eur. J. Cancer, 40, 1872, 10.1016/j.ejca.2004.04.032

Hensing, 2006, Anti-Cancer Drugs, 17, 697, 10.1097/01.cad.0000215054.62942.7f

Scagliotti, 2003, Lung Cancer, 41, S223, 10.1016/S0169-5002(03)92490-1

Calvert, 2001, Eur. J. Cancer, 37, S260, 10.1016/S0959-8049(01)81457-X

Kelland, 1993, Cancer Res., 53, 2581

Samimi, 2006, Cancer Chemother. Pharmacol., 57, 781, 10.1007/s00280-005-0121-5

Choy, 2008, Clin. Cancer Res., 14, 1633, 10.1158/1078-0432.CCR-07-2176

Fokkema, 2002, Biochem. Pharmacol., 63, 1989, 10.1016/S0006-2952(02)00983-8

Cmelak, 1999, Proc. Am. Soc. Clin. Oncol., 18

Holford, 1998, Anti-cancer Drug Des., 13, 1

Battle, 2006, Inorg. Chem., 45, 6317, 10.1021/ic060273g

Beale, 2003, Br. J. Cancer, 88, 1128, 10.1038/sj.bjc.6600854

Chen, 1998, Chem.–Eur. J., 4, 672, 10.1002/(SICI)1521-3765(19980416)4:4<672::AID-CHEM672>3.0.CO;2-8

Holford, 1998, Br. J. Cancer, 77, 366, 10.1038/bjc.1998.59

Sharp, 2002, Eur. J. Cancer, 38, 2309, 10.1016/S0959-8049(02)00244-7

Raynaud, 1997, Clin. Cancer Res., 3, 2063

Gelmon, 2003, Ann. Oncol., 14, 543, 10.1093/annonc/mdg171

Treat, 2002, Eur. J. Cancer, 38

Sood, 2006, Bioconjugate Chem., 17, 1270, 10.1021/bc0600517

Giansi, 1999, Eur. J. Cancer

Duncan, 1997, Chem. Ind., 7, 262

Rice, 2006, Clin. Cancer Res., 12, 2248, 10.1158/1078-0432.CCR-05-2169

Campone, 2007, Cancer Chemother. Pharmacol., 60, 523, 10.1007/s00280-006-0397-0

nowotnik, 2009, Adv.Drug Delivery Rev., 61, 1214, 10.1016/j.addr.2009.06.004

Viens, 2001, Eur. J. Cancer, 37, S323, 10.1016/S0959-8049(01)81689-0

Boulikas, 2004, Oncol. Rep., 12, 3

Boulikas, 2007, Cancer Ther., 5, 351

Stathopoulos, 2005, Oncol. Rep., 13, 589

Kwok, 2001, Annu. Rev. Genomics Hum. Genet., 2, 235, 10.1146/annurev.genom.2.1.235

Stathopoulos, 2006, Oncol. Rep., 15, 1201

Froudarakis, 2008, Cancer, 113, 2752, 10.1002/cncr.23921

Boulikas, 2005, Anticancer Res., 25, 3031

Ravaioli, 2009, J. Chemotherapy (Italy), 21, 86, 10.1179/joc.2009.21.1.86

Mylonakis, 2010, Lung Cancer, 68, 240, 10.1016/j.lungcan.2009.06.017

Kosmas, 2009, Eur. J. Cancer Suppl., 7, 531, 10.1016/S1359-6349(09)71801-4

Karpathiou, 2007, Oncology, 73, 426, 10.1159/000136800

Schildhauer, 2005, Eur. J. Cancer Suppl., 3, 286

Jehn, 2007, Oral Oncology Supplement, 2, 118, 10.1016/S1744-7895(07)70239-0

Koukourakis, 2010, Int. J. Radiat. Oncol., Biol., Phys., 10.1016/j.ijrobp.2009.07.1733